» Articles » PMID: 11665973

Traditional Framingham Risk Factors Fail to Fully Account for Accelerated Atherosclerosis in Systemic Lupus Erythematosus

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 2001 Oct 23
PMID 11665973
Citations 404
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The frequency of coronary heart disease (CHD) and stroke are increased in systemic lupus erythematosus (SLE), but the extent of the increase is uncertain. We sought to determine to what extent the increase could not be explained by common risk factors.

Methods: The participants at two SLE registries were assessed retrospectively for the baseline level of the Framingham study risk factors and for the presence of vascular outcomes: nonfatal myocardial infarction (MI), death due to CHD, overall CHD (nonfatal MI, death due to CHD, angina pectoris, and congestive heart failure due to CHD), and stroke. For each patient, the probability of the given outcome was estimated based on the individual's risk profile and the Framingham multiple logistic regression model, corrected for observed followup. Ninety-five percent confidence intervals (95% CIs) were estimated by bootstrap techniques.

Results: Of 296 SLE patients, 33 with a vascular event prior to baseline were excluded. Of the 263 remaining patients, 34 had CHD events (17 nonfatal MIs, 12 CHD deaths) and 16 had strokes over a mean followup period of 8.6 years. After controlling for common risk factors at baseline, the increase in relative risk for these outcomes was 10.1 for nonfatal MI (95% CI 5.8-15.6), 17.0 for death due to CHD (95% CI 8.1-29.7), 7.5 for overall CHD (95% CI 5.1-10.4), and 7.9 for stroke (95% CI 4.0-13.6).

Conclusion: There is a substantial and statistically significant increase in CHD and stroke in SLE that cannot be fully explained by traditional Framingham risk factors alone.

Citing Articles

Coronary artery calcification progression and renal involvement in patients with systemic lupus erythematosus: a longitudinal cohort study.

Zinglersen L, Zinglersen A, Myhr K, Hermansen M, Kofoed K, Fuchs A Rheumatol Int. 2025; 45(1):26.

PMID: 39804493 PMC: 11729070. DOI: 10.1007/s00296-025-05785-8.


Prevalence of cardiovascular events in a population-based registry of patients with systemic lupus erythematosus.

Joyce D, Berger J, Guttmann A, Hasan G, Buyon J, Belmont H Arthritis Res Ther. 2024; 26(1):160.

PMID: 39272198 PMC: 11401284. DOI: 10.1186/s13075-024-03395-6.


Learning from serum markers reflecting endothelial activation: longitudinal data in childhood-onset systemic lupus erythematosus.

Bergkamp S, Bergkamp N, Wahadat M, Gruppen M, Nassar-Sheikh Rashid A, Tas S Lupus Sci Med. 2024; 11(2).

PMID: 39242108 PMC: 11381702. DOI: 10.1136/lupus-2024-001190.


Deciphering Mechanisms, Prevention Strategies, Management Plans, Medications, and Research Techniques for Strokes in Systemic Lupus Erythematosus.

Al-Ewaidat O, Naffaa M Medicines (Basel). 2024; 11(7).

PMID: 39189161 PMC: 11348055. DOI: 10.3390/medicines11070015.


The 100 top-cited studies in systemic lupus erythematosus: A bibliometric analysis.

Quan L, Dai J, Luo Y, Wang L, Liu Y, Meng J Hum Vaccin Immunother. 2024; 20(1):2387461.

PMID: 39149877 PMC: 11328883. DOI: 10.1080/21645515.2024.2387461.